Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer.
chronic plasmatic exposure
kinase inhibitors
non-small cell lung cancer
oncogene addiction
resistance mutation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 Dec 2020
14 Dec 2020
Historique:
received:
03
12
2020
accepted:
10
12
2020
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
18
12
2020
Statut:
epublish
Résumé
Kinase inhibitors (KI) have dramatically improved the outcome of treatment in patients with non-small cell lung cancer (NSCLC), which harbors an oncogene addiction. This study assesses KI plasma levels and their clinical relevance in patients chronically exposed to KIs. Plasma samples were collected in NSCLC patients receiving erlotinib, gefitinib, osimertinib, crizotinib, or dabrafenib (with or without trametinib) for at least three months between November 2013 and February 2019 in a single institution. KI drug concentrations were measured by ultra-performance liquid chromatography coupled with tandem mass spectrometry and compared to published data defining optimal plasma concentration. The main outcome was the rate of samples with suboptimal KI plasma concentrations. Secondary outcomes included its impact on
Identifiants
pubmed: 33327482
pii: cancers12123758
doi: 10.3390/cancers12123758
pmc: PMC7764991
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Pharmacokinet. 2014 Apr;53(4):305-25
pubmed: 24566736
ESMO Open. 2018 Nov 5;3(7):e000445
pubmed: 30498581
Clin Pharmacokinet. 2017 Jul;56(7):683-688
pubmed: 28101705
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71
pubmed: 16609030
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Invest New Drugs. 2012 Oct;30(5):2046-9
pubmed: 22038662
Ther Drug Monit. 2014 Jun;36(3):326-34
pubmed: 24305627
Eur J Cancer. 2014 Aug;50(12):2020-36
pubmed: 24928190
Clin Cancer Res. 2019 Mar 1;25(5):1479-1485
pubmed: 30765389
J Clin Oncol. 2018 Mar 20;36(9):911-919
pubmed: 29401004
Ther Drug Monit. 2009 Oct;31(5):579-84
pubmed: 19730279
Clin Pharmacol Ther. 2017 Nov;102(5):765-776
pubmed: 28699160
Eur J Clin Pharmacol. 2019 Sep;75(9):1309-1318
pubmed: 31175385
Crit Rev Oncol Hematol. 2019 Sep;141:112-124
pubmed: 31276964
Lancet Oncol. 2014 Jul;15(8):e315-26
pubmed: 24988935
J Pharm Biomed Anal. 2018 Sep 5;158:174-183
pubmed: 29883880
Oncologist. 2014 Aug;19(8):e3
pubmed: 25052452
Pharmacopsychiatry. 2018 Jan;51(1-02):9-62
pubmed: 28910830
J Clin Oncol. 2020 Aug 20;38(24):2762-2772
pubmed: 32568632
J Clin Oncol. 2010 May 10;28(14):2381-8
pubmed: 20385986